The FDA has agreed to review a European botulism toxin product that, if approved, would compete with Botox. The new face freezer is made by a French drug company called Ipsen and is licensed in 23 countries. If it gets the go-head it will be marketed under the name of Reloxin and will be, more or less, the same kind of poison as in Botox and is likely to raise the same safety concerns - recent animal tests on Botox revealed that it can seep to the brain. Last year Allergan, which owns the Botox patent, sold over $1 billion worth of the product.